علاج سرطان القناة الموضعي منخفض أو متوسط الدرجة في الثدي لدى المرضى الذين تبلغ أعمارهم 40 عاماً أو أكبر

References

DOI: 10.1093/jjco/hyae122

• The eligibility criteria in the two trials were almost the same (NG 1, NG 2, tumor diameter <2.5 cm and negative resection margin).
• The aim of this trial is to determine whether administration of low-dose tamoxifen (5 mg/day for 5 years) is non-inferior to RT (50 Gy in 25 fractions or 40.05 Gy in 15 fractions) for preventing IBTR in patients with low-risk characteristics (> 40 years old, low BRCA1/2 risk: Manchester Score < 10, mammographically detected unicentric and non-mass lesions, low- or intermediate-grade without comedo or necrosis, measuring <2.5 cm in diameter with a tumor-free margin of ≥3 mm, and ER-positive status) of DCIS.
• The NCCN guidelines state that low-dose tamoxifen (5 mg/day or 10 mg/every other day for 3 years) is a reasonable treatment option for patients who are symptomatic or unwilling to take the standard 20-mg dose.
• The TAM-01 trial was a phase III RCT conducted to verify the efficacy and safety of low-dose tamoxifen (5 mg/day for 3 years) after partial resection of the breast in patients with hormone-sensitive high-risk breast lesions.